Cargando…

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies

Digestive system malignancies are one of the primary causes of cancer-related death. Meanwhile, angiogenesis has been proved to play an important role in the process of cancer neovascularization. Apatinib, a novel targeted antiangiogenic molecule, could generate highly selective competition in the v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Haosheng, Huang, Haiyan, Zhang, Tao, Feng, Haoran, Wang, Shaodong, Zhang, Yaqi, Ji, Xiaopin, Cheng, Xi, Zhao, Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276937/ https://www.ncbi.nlm.nih.gov/pubmed/35844616 http://dx.doi.org/10.3389/fimmu.2022.937307

Ejemplares similares

Colorectal cancer vaccines: The current scenario and future prospects
por: Jia, Wenqing, et al.
Publicado: (2022)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging
por: Liang, Qian, et al.
Publicado: (2019)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019)

Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
por: Xuan, Tian-Tian, et al.
Publicado: (2022)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Single-docking robotic assisted proctectomy for rectal cancer below peritoneal reflection: a propensity score matching analysis
por: Zhang, Tao, et al.
Publicado: (2021)

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Clinical Status and Future Prospects of Transanal Total Mesorectal Excision
por: Guo, Zichao, et al.
Publicado: (2022)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022)

Single-incision robotic assisted surgery: a nonrandomized cohort pilot study on a novel surgical platform in colorectal surgery
por: Guo, Zichao, et al.
Publicado: (2023)

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
por: Hu, Haoyue, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
por: Ai, Huihan, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
por: Furukawa, Koichi, et al.
Publicado: (2020)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer
por: Ren, Qianhe, et al.
Publicado: (2023)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

LongTerm Outcomes of Three-Port Laparoscopic Right Hemicolectomy Versus Five-Port Laparoscopic Right Hemicolectomy: A Retrospective Study
por: Zhang, Tao, et al.
Publicado: (2021)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

γδ T cells in immunotherapies for B-cell malignancies
por: Rimailho, Léa, et al.
Publicado: (2023)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?
por: García-Martínez, Elena, et al.
Publicado: (2020)

Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
por: Ji, Zhi, et al.
Publicado: (2020)

A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts
por: Ren, Qianhe, et al.
Publicado: (2023)

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review
por: Li, Jiayi, et al.
Publicado: (2022)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023)

Editorial: Immunological characteristics of malignant tumors of the hepatobiliary system and identification of immunotherapy targets
por: Zhang, Qiyao, et al.
Publicado: (2023)

Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
por: Ahluwalia, Manmeet S., et al.
Publicado: (2010)

Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
por: Haidl, Friederike, et al.
Publicado: (2017)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_onlt4vrpplutradevnqnngfvhj